ArticleBMC infectious diseases2022
Adverse effects following COVID-19 vaccination in Iran.
Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 57 citations in OpenAlex.
- Adverse events of special interest after vaccination with COVID-19 vaccines: a cohort event monitoring study in Iran.European journal of medical research · 2025Article
- Article
- Monitoring and active surveillance of adverse events following the booster dose of AZD1222 vaccine in people vaccinated with Sinopharm BBIBP-CorV: a cohort study.BMC public health · 2025Article
- Factors associated with severe adverse events following COVID-19 vaccine: a multicenter study in the Casablanca-Settat region of Morocco.The Pan African medical journal · 2025Article
- Impact of COVID-19 on Guillain Barre Syndrome (GBS) insights from an Iranian referral center.Frontiers in neurology · 2025Article
- Report on adverse events of COVID-19 vaccines in Iran: a comprehensive national prospective longitudinal analysis.Frontiers in immunology · 2025Article
- Comparison of T cells mediated immunity and side effects of mRNA vaccine and conventional COVID-19 vaccines administrated in Jordan.Human vaccines & immunotherapeutics · 2024Article
- Side effects associated with homogenous and heterogenous doses of Oxford-AstraZeneca vaccine among adults in Bangladesh: an observational study.Scientific reports · 2024Observational
- Article
- The effectiveness of COVID-19 vaccination in preventing hospitalisation and mortality: A nationwide cross-sectional study in Iran.Journal of global health · 2024Article
- Exploring the perceptions and experiences of mobile teams on COVID-19 vaccine uptake at the community level: evidence from Benue and Niger states.BMC public health · 2024Article
- Surveillance of COVID-19 vaccines: A comprehensive analysis of the first immunization drive in Ecuador.Heliyon · 2024Article
- Perinatal outcomes and sinopharm BBIBP-CorV vaccination during pregnancy.BMC pregnancy and childbirth · 2024Article
- Changes in emergency department visits and mortality during the COVID-19 pandemic: a retrospective analysis of 956 hospitals.Archives of public health = Archives belges de sante publique · 2024Article
- Reported side-effects following Oxford/AstraZeneca COVID-19 vaccine in the north-west province, Iran: A cross-sectional study.PloS one · 2024Article
- COVID-19 vaccines breakthrough infection and adverse reactions in medical students: a nationwide survey in Iran.Frontiers in public health · 2024Article
- Patient Presentations in a Community Pain Clinic after COVID-19 Infection or Vaccination: A Case-Series Approach.Clinics and practice · 2023Article
- Article
- Pernicious Anemia Following COVID-19 Vaccination: A Report of Two Cases.International journal of hematology-oncology and stem cell research · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundVaccination is a key intervention to prevent COVID-19. Many vaccines are administered globally, yet there is not much evidence regarding their safety and adverse effects. Iran also faces this challenge, especially as data regarding the Sputnik V vaccine is sparse. Therefore, the aim of this study is to determine the adverse effects of the most commonly used vaccines in Iran.
methodsUsing a retrospective cohort study design, 6600 subjects aged 18 years or older who had received two doses of any of the three COVID-19 vaccines (Sinopharm, AstraZeneca, and Sputnik V) were selected using a random sampling method between March and August 2021. Subjects were asked about any adverse effects of the vaccines by trained interviewers via telephone interview. Vaccine-related adverse effects in individuals during the first 72 h and subsequently following both doses of the vaccines were determined. The demographic variables, type of administered vaccine, adverse effects, and history of the previous infection with COVID-19 were collected. Descriptive statistics (mean, standard deviation) and analytical statistics (Chi-squared and Wilcoxon tests) were performed at a 95% significance level using STATA software version 15 (STATA Corp, College Station, TX, USA).
resultsFrom 6600 participants, 4775 responded (response rate = 72.3%). Of the participants, 1460 (30.6%) received the AstraZeneca vaccine, 1564 (32.8%) received the Sinopharm vaccine and 1751 (36.7%) received the Sputnik V vaccine. 2653 participants (55.56%) reported adverse effects after the first dose and 1704 (35.7%) after the second dose. Sputnik V caused the most adverse effects with 1449 (82.7%) vaccine recipients reporting symptoms after the first or second dose, compared with 1030 (70.5%) for AstraZeneca and only 585 (37.4%) for the Sinopharm vaccine. The most common adverse effects after the first dose were fatigue (28.37%), chill/fever (26.86%), and skeletal pain (22.38%). These three adverse effects were the same for the second dose, although their prevalence was lower.
conclusionsIn this study, we demonstrate that the Sputnik V vaccine has the highest rate of adverse effects, followed by the AstraZeneca and Sinopharm vaccines. COVID-19 vaccines used in Iran are safe and there were no reports of serious adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.